Pacific Biosciences Of California (PACB) Restructuring Costs (2021 - 2023)
Pacific Biosciences Of California's (PACB) quarterly Restructuring Costs came in at $63000.0 in Q4 2023, down 99.3% quarter-over-quarter from $9.0 million in Q3 2023.
Pacific Biosciences Of California (PACB) Restructuring Costs (2021 - 2023) Analysis & Trends
Pacific Biosciences Of California's Restructuring Costs history runs 2 years deep, the most recent figure standing at $63000.0 for Q4 2023.
- On a quarterly basis, Restructuring Costs changed N/A year-over-year to $63000.0 in Q4 2023; TTM through Dec 2024 was $9.0 million, a N/A change from a year earlier, with the FY2023 full-year figure at $9.0 million, changed N/A from the prior year.
- Restructuring Costs eased to $63000.0 in Q4 2023 per PACB's latest filing, from $9.0 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $12.0 million in Q3 2021 and bottomed at $63000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Pacific Biosciences Of California | 428.15 Mn | 152.18 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 63,000.00 |
| Sep 30, 2023 | 8.98 Mn |
| Dec 31, 2021 | 403,000.00 |
| Sep 20, 2021 | 12.00 Mn |